12:00 AM
May 03, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adcon-L: Marketed

Researchers presented Phase IV data showing that 50 Adcon-L patients, who had previously undergone spinal surgery and then received Adcon-L in a second surgery, had a 54 percent reduction...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >